Modeling Alzheimer’s Disease with Certara IQ™ Video Modeling Alzheimer’s Disease with Certara IQ™ Explore Certara IQ’s Alzheimer’s Disease model, enabling researchers to simulate neurodegenerative pathways, test therapies, and…Certara2025 年 10 月 16 日
Early Feasibility Assessment (EFA) with Certara IQ™ Video Early Feasibility Assessment (EFA) with Certara IQ™ Learn how Certara IQ performs early feasibility assessments (EFA) to predict biotherapeutic dosing, guide candidate…Certara2025 年 10 月 16 日
Certara IQ™: Predicting Recommended Phase 2 Doses with Confidence Video Certara IQ™: Predicting Recommended Phase 2 Doses with Confidence Learn how Certara IQ predicts recommended Phase 2 doses using advanced QSP modeling workflows that…Certara2025 年 10 月 16 日
Certara IQ™: Model-Informed First-In-Human (FIH) Dose Selection Video Certara IQ™: Model-Informed First-In-Human (FIH) Dose Selection Discover how Certara IQ uses QSP modeling to predict safe and effective First-In-Human doses, accelerating…Certara2025 年 10 月 16 日
Inside Certara IQ™: Building the Future of QSP with Josh Apgar & Chris Bouton Video Inside Certara IQ™: Building the Future of QSP with Josh Apgar & Chris Bouton Hear from Certara experts on how Certara IQ modernizes QSP modeling with AI, collaboration tools,…Certara2025 年 10 月 16 日
PKUK 2025 Pre-Conference Workshop: Modeling & Simulation Updates – QSP and PK/PD Software Live Events PKUK 2025 Pre-Conference Workshop: Modeling & Simulation Updates – QSP and PK/PD Software – Scarman, Coventry, UKCertara2025 年 10 月 14 日
C-QTc and C-QT Analysis: Replacing TQT Studies and Accelerating Cardiovascular Safety Decisions White Paper C-QTc and C-QT Analysis: Replacing TQT Studies and Accelerating Cardiovascular Safety Decisions Replace or waive TQT studies with validated C-QT analysis strategies accepted by FDA, EMA, PMDA.…Certara2025 年 10 月 3 日
Certara & Dizal Partner to Fast-Track FDA Approval of Sunvozertinib for Lung Cancer Case Study Certara 与迪哲强强联手助力舒沃替尼斩获FDA肺癌适应症加速批准 Certara’s support enabled fast-track FDA oncology approval 2025 for Sunvozertinib, a breakthrough NSCLC therapy targeting…Certara2025 年 10 月 2 日